

HCV -SPECIAL REGISTRY

PSG-VITAL UNIFORM GUIDELINE - PUERTO RICO HEALTH INSURANCE ADMINISTRATION

Special Condition	Definitive diagnosis criteria for inclusion in the coverage	Special Coverage Effectiveness and Duration	Services included in Special Coverage	Risk Allocation
<p>HCV (Chronic Hepatitis C)</p>	<p>Patient diagnoses with Chronic HCV as established in ASES' policy:</p> <p>"Policy for the management of patients diagnosed with Chronic Hepatitis-C under the GHIP"</p> <p>For its registry will be necessary to submit evidence of the following:</p> <ul style="list-style-type: none"> • Positive result for HCV antibody (Ab) test • and Quantitative RNA test 	<p>Effectiveness= The Special Coverage for the treatment of HCV will start once the patient is registered under special coverage with the MCO by the PCP or the specialist that made the diagnosis.</p> <p>Duration= HCV special coverage will be in effect since the time the patient is registered on this special cover until six (6) months after completing treatment with the direct-acting antiviral drug (DDA) with evidence of sustained virological response not detected.</p>	<ol style="list-style-type: none"> 1. Direct access to the specialist or subspecialist that handles condition without referral of the PCP. 2. Treatment with the direct-acting antiviral drug (DDA) established under the Coverage of medication of ASES without countersignature of the PCP. 3. Medically Necessary Laboratories without referral of the PCP. 4. Imaging, sonography, MRI, CT or any other radiological imagine medically necessary without referral of the PCP. 	<p>Insurer- Medical services as defined for the special coverage condition in this document. Including but not limited to: Laboratories, (CMP, PT & INR, CBC, Renal function test's, genotype, RNA quantitative, resistant test as needed, radiological imagines (sonogram, =with and w/o elastography, Liver CT and MRI if clinically indicated)and or any other medically necessary laboratories or tests to identify gradation and estimated degree of liver fibrosis in Hepatitis C, including liver biopsy with or w/o imaging guidance, & pathology report.</p> <p>Also included are the visits to Gastroenterologist or other specialized authorized physician as described in the "Policy for the management of patients diagnosed with Chronic Hepatitis-C under the GHIP"</p> <p>Laboratories, tests, imaging studies and interventional radiologist evaluation, biopsy and pathological report are covered from the moment the patient is included in the special coverage and until</p>

				<p>discharged from the special coverage inclusion.</p> <p>The recommended follow up during the medical treatment is included in the “Policy for the management of patients diagnosed with Chronic Hepatitis-C under the GHIP” as guidelines. (see pages 22-23).</p> <p>GMP/PCP: Will receive the monthly capitation corresponding to the insured.</p> <p>ASES: Pharmacological treatment with direct-acting antiviral drug (DDA).</p>
--	--	--	--	--